Published in Evid Based Complement Alternat Med on August 25, 2015
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2009) 12.34
miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature (2009) 10.26
MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer (2006) 5.37
MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev (2009) 4.62
Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J (2010) 4.47
MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res (2009) 4.25
Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood (2010) 2.80
Essential hypertension. Lancet (2007) 2.63
Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation (2011) 2.60
Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet (2010) 2.05
down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J Biol Chem (2011) 1.79
MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ Res (2011) 1.67
MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J Cell Physiol (2011) 1.64
Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J Mol Cell Cardiol (2011) 1.54
Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens (2004) 1.22
MicroRNAs in cardiovascular biology and heart disease. Circ Cardiovasc Genet (2009) 1.19
MicroRNA-204 regulates vascular smooth muscle cell calcification in vitro and in vivo. Cardiovasc Res (2012) 1.14
Bone morphogenetic protein 4 promotes vascular smooth muscle contractility by activating microRNA-21 (miR-21), which down-regulates expression of family of dedicator of cytokinesis (DOCK) proteins. J Biol Chem (2011) 1.10
The miR-143/145 cluster is a novel transcriptional target of Jagged-1/Notch signaling in vascular smooth muscle cells. J Biol Chem (2011) 1.10
Cross talk between microRNA and coding cancer genes. Cancer J (2012) 1.06
Insulin promotes vascular smooth muscle cell proliferation via microRNA-208-mediated downregulation of p21. J Hypertens (2011) 1.00
MicroRNA-20a inhibits stress-induced cardiomyocyte apoptosis involving its novel target Egln3/PHD3. J Mol Cell Cardiol (2011) 0.99
Effect of Chinese herbal medicine for calming Gan (肝) and suppressing hyperactive yang on arterial elasticity function and circadian rhythm of blood pressure in patients with essential hypertension. Chin J Integr Med (2011) 0.95
miR-20a represses endothelial cell migration by targeting MKK3 and inhibiting p38 MAP kinase activation in response to VEGF. Angiogenesis (2012) 0.84
MicroRNA-375, a new regulator of cadherin-7, suppresses the migration of chondrogenic progenitors. Cell Signal (2012) 0.82
Hemin inhibits hypertensive rat vascular smooth muscle cell proliferation through regulation of cyclin D and p21. Arch Pharm Res (2009) 0.82
Extension of microRNA expression pattern associated with high-risk neuroblastoma. Tumour Biol (2013) 0.79
[Clinical efficacy study on calming liver and restraining Yang formula in treating patients with mild or moderate degree of essential hypertension]. Zhongguo Zhong Yao Za Zhi (2010) 0.77
Qindan capsule changes adventitial collagen synthesis in spontaneously hypertensive rats. Chin J Integr Med (2013) 0.76
iTRAQ-Based Quantitative Proteomics Analysis of the Protective Effect of Yinchenwuling Powder on Hyperlipidemic Rats. Evid Based Complement Alternat Med (2017) 0.75